Literature DB >> 30972454

Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy.

Simon Kirste1,2, Nicole Landenberger3,4, Jutta Scholber3,4, Karl Henne3,4, Uwe A Wittel5, Anca-Ligia Grosu3,4.   

Abstract

BACKGROUND: We describe the clinical history, outcome, and toxicity of five patients with high-grade retroperitoneal soft tissue sarcoma (RSTS) who were treated with neoadjuvant low-dose radiotherapy (RT) followed by resection with or without intraoperative radiotherapy (IORT), followed by adjuvant RT. We aim to provide additional evidence for the various treatment options that exist for this rare tumor entity.
METHODS: Most patients presented with mild abdominal symptoms. Diagnosis was confirmed by biopsy. Additional imaging was done by sonography, magnetic resonance imaging (MRI), and/or positron emission tomography (PET)/computed tomography (CT). All patients were treated with neoadjuvant RT of 19.8 Gy in 1.8-Gy fractions followed by resection and postoperative RT up to 45 Gy with a median interval between resection and start of postoperative RT of 5 weeks. Two patients received additional IORT. Median follow-up was 61 months.
RESULTS: One patient developed a local recurrence that was diagnosed 30 months after the start of the first therapy. He was treated with a salvage resection and had no evidence of disease at the last follow-up. Another patient developed a right-sided RSTS on the contralateral side from the primary radiation field with pelvic bone infiltration 56 months after the start of RT. He was treated again by RT and resection and was without evidence of disease at last follow-up. Radiotherapy was well tolerated without major toxicity.
CONCLUSION: The treatment of RSTS by low-dose neoadjuvant RT, resection with IORT and adjuvant RT seems to be a feasible and effective treatment approach. Further studies comparing neoadjuvant with adjuvant RT are necessary to find the best treatment option.

Entities:  

Keywords:  Adjuvant treatment; High-grade sarcoma; Intraoperative radiotherapy; Resection; Wound complications

Mesh:

Year:  2019        PMID: 30972454     DOI: 10.1007/s00066-019-01464-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  29 in total

1.  Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management.

Authors:  M J Heslin; J J Lewis; E Nadler; E Newman; J M Woodruff; E S Casper; D Leung; M F Brennan
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

2.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; N Abecassis; H T Aro; S Bauer; R Biagini; S Bielack; S Bonvalot; I Boukovinas; J V M G Bovee; T Brodowicz; J M Broto; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; M Eriksson; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; B Kasper; K Kopeckova; D A Krákorová; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

Review 3.  Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel.

Authors:  Elizabeth H Baldini; Dian Wang; Rick L M Haas; Charles N Catton; Daniel J Indelicato; David G Kirsch; David Roberge; Kilian Salerno; Curtiland Deville; B Ashleigh Guadagnolo; Brian O'Sullivan; Ivy A Petersen; Cecile Le Pechoux; Ross A Abrams; Thomas F DeLaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-01       Impact factor: 7.038

Review 4.  [Pre- or postoperative radiotherapy essential for the treatment of retroperitoneal sarcomas].

Authors:  Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2016-11       Impact factor: 3.621

5.  Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.

Authors:  E Stoeckle; J M Coindre; S Bonvalot; G Kantor; P Terrier; F Bonichon; B Nguyen Bui
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

Review 6.  Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience.

Authors:  Robert A Zlotecki; Teri S Katz; Christopher G Morris; D Scott Lind; Steven N Hochwald
Journal:  Am J Clin Oncol       Date:  2005-06       Impact factor: 2.339

7.  Long-term Oncologic Outcomes After Neoadjuvant Radiation Therapy for Retroperitoneal Sarcomas.

Authors:  Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Brian R Englum; David G Kirsch; Douglas S Tyler; Dan G Blazer
Journal:  Ann Surg       Date:  2015-07       Impact factor: 12.969

8.  Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas.

Authors:  Christopher P Cannon; Matthew T Ballo; Gunar K Zagars; Attiqa N Mirza; Patrick P Lin; Valerae O Lewis; Alan W Yasko; Robert S Benjamin; Peter W T Pisters
Journal:  Cancer       Date:  2006-11-15       Impact factor: 6.860

9.  Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas.

Authors:  Sam S Yoon; Yen-Lin Chen; David G Kirsch; Ugwuji N Maduekwe; Andrew E Rosenberg; G Petur Nielsen; Dushyant V Sahani; Edwin Choy; David C Harmon; Thomas F DeLaney
Journal:  Ann Surg Oncol       Date:  2010-02-12       Impact factor: 5.344

10.  Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database.

Authors:  Daniel P Nussbaum; Christel N Rushing; Whitney O Lane; Diana M Cardona; David G Kirsch; Bercedis L Peterson; Dan G Blazer
Journal:  Lancet Oncol       Date:  2016-05-17       Impact factor: 41.316

View more
  3 in total

Review 1.  Retroperitoneal Sarcomas: a Current Review on Management.

Authors:  Shraddha Patkar; Abhay K Kattepur; Nehal Khanna; Jyoti Bajpai
Journal:  Indian J Surg Oncol       Date:  2022-02-21

2.  Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03).

Authors:  Jens Jakob; Tom Lesluyes; Anna Simeonova-Chergou; Frederik Wenz; Peter Hohenberger; Frederic Chibon; Sophie Le Guellec
Journal:  Strahlenther Onkol       Date:  2019-11-15       Impact factor: 3.621

3.  Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome.

Authors:  A Willner; K Fechner; A Agaimy; F Haller; M Eckstein; O J Ott; F Putz; U S Gaipl; S Kersting; N Meidenbauer; R Grützmann; R Fietkau; S Semrau
Journal:  Strahlenther Onkol       Date:  2021-11-04       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.